This page shows the latest Relvar news and features for those working in and with pharma, biotech and healthcare.
New asthma and COPD drugs such as Relvar/Breo (vilanterol/fluticasone furoate) and Anoro (vilanterol/umeclidinium bromide) added £243m ($319m) in the quarter, more than offsetting a 13% decline in Seretide
These include GSK's Relvar/Breo (vilanterol/fluticasone furoate) and Anoro (vilanterol/umeclidinium bromide), as well as Novartis' Ultibro (glycopyrronium/indacaterol), AZ's own Duaklir (aclidinium bromide/formoterol fumarate) and Boehringer
The company suffered declining respiratory sales through 2015 - although its performance improved in the first quarter of this year thanks to gathering momentum for two-drug combinations Relvar/Breo (vilanterol/fluticasone
Relvar/Breo (vilanterol/fluticasone furoate), Anoro (vilanterol/umeclidinium bromide) and severe asthma debutante Nucala (mepolizumab).
GlaxoSmithKline's struggling respiratory division has had more bad news, with new product Breo/Relvar failing to improve survival in a trial involving patients with chronic obstructive pulmonary disease (COPD).
Relvar (fluticasone furoate/vilanterol) which became the first once-daily product of its type, have injected more competition into the marketplace.
More from news
Approximately 2 fully matching, plus 28 partially matching documents found.